Non-Medical Switches of Biosimilar in Psoriasis Treatment Appears Safe

Christoffer Willy Schwarz presented a real-world study at EADV 2024 on non-medical switches between adalimumab products in psoriasis patients. Among 180 patients, the risk of discontinuation within six months was 0-8%, with the highest rate (8%) linked to switching from the reference drug to a biosimilar. The results suggest switching is generally safe, although the study is limited by its size and scope.